Özgür Açıkgöz

9PUBLICATIONS
20CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Models of care and place of birthChemotherapyAllergy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|May 04, 2026
Combined Lung Immune Prognostic Index (LIPI)-Glasgow Prognostic Score (GPS) as a Prognostic Tool in Extensive-Stage Small-Cell Lung Cancer Treated with First-Line Chemo-Immunotherapy.

|May 04, 2026
A Novel Biological Index for Predicting Neoadjuvant Treatment Response in HER2-Positive Breast Cancer: The Tumor-Immune-Proliferation-Inflammation (TIPI) Score.

|Mar 28, 2026
Immunotherapy Versus Chemo-Immunotherapy as First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with PD-L1 TPS ≥ 50%: A Real-World Retrospective Study.

Maral Martin Mildanoglu, Mehmet Haluk Yucel, Ebru Engin Delipoyraz

|May 14, 2025
Clinical Outcomes in Early-Stage HER2-Low and HER2-Zero Breast Cancer: Single-Center Experience.

Jamshid Hamdard, Mehmet Haluk Yücel, Harun Muğlu

|May 01, 2025
The Prognostic and Predictive Roles of Ataxia-Telangiectasia Mutated (ATM) Expression in Patients with Metastatic Non-Small-Cell Lung Cancer Receiving Pembrolizumab Monotherapy Alone or in Combination with Chemotherapy.

Jamshid Hamdard, Harun Muğlu, Ahmet Bilici

|Apr 12, 2025
Clinicopathological Characteristics of Extrapulmonary Neuroendocrine Carcinomas: Treatment Responses and Survival Outcomes: Single-Center Experience.

Harun Muğlu, Erdem Sünger, Maral Martin Mıldanoğlu

Pageof 2

Frequent Collaborators

8 joint publications

Ahmet Bilici

7 joint publications

Jamshid Hamdard

7 joint publications

Harun Muglu

5 joint publications

Mehmet Haluk Yucel